Eric Reiner
Yale University
10 Papers
63 Citations
Eric Reiner is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Precision medicine. The author has an hindex of 5, co-authored 9 publications.
Chat about Author
Papers
Extraction of a Micra Transcatheter Pacing System: First-in-human experience
TL;DR: The first successful extraction of a Micra Transcatheter Pacing System is reported, 3 weeks after initial device implantation, with the potential for a significant decrease in many of the risks associated with conventional pacing systems.
45
Initial experience with 3% sodium tetradecyl sulfate foam and fibered coils for management of adolescent varicocele.
TL;DR: The use of 3% STS foam in combination with pushable fibered coils is a safe and effective sclerosing procedure for adolescent subjects with varicocele.
23
Clinical outcome of the Tal Palindrome chronic hemodialysis catheter: single institution experience.
Marcelo Spector,Hamid Mojibian,Donna Eliseo,Jeffrey Pollak,Eric Reiner,Melih Arici,Michael G. Tal +6 more
TL;DR: Clinical experience with the Tal Palindrome hemodialysis catheter demonstrated safe and reliable use with low infection rates.
21
Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools
Jaymin M. Patel,Joshua Knopf,Eric Reiner,Veerle Bossuyt,Lianne Epstein,Michael P. DiGiovanna,Gina G. Chung,Andrea Silber,Tara Sanft,Erin Hofstatter,Sarah S. Mougalian,Maysa M. Abu-Khalaf,James T. Platt,Weiwei Shi,Peter Gershkovich,Christos Hatzis,Lajos Pusztai +16 more
TL;DR: Targeted sequencing of 315 genes from 75 metastatic breast cancer biopsies using the FoundationOne assay indicated further development and standardization of broadly applicable software tools that assist in the therapeutic interpretation of genomic data is needed.
The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma
Susanne Smolka,Julius Chapiro,Wilfred Manzano,John Treilhard,Eric Reiner,Yanhong Deng,Yan Zhao,Bernd Hamm,James S. Duncan,Bernhard Gebauer,MingDe Lin,Jean Francois H. Geschwind +11 more
TL;DR: Anti-angiogenic therapy with bevacizumab does not impede early response assessment by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria.
8